tetano
Editor, Senior Moderator
J Med Biochem
. 2021 Sep 3;40(4):335-340.
doi: 10.5937/jomb0-31475.
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
Elisa Danese[SUP] 1 [/SUP], Martina Montagnana[SUP] 1 [/SUP], Gian Luca Salvagno[SUP] 1 2 [/SUP], Matteo Gelati[SUP] 1 [/SUP], Denise Peserico[SUP] 1 [/SUP], Laura Pighi[SUP] 1 [/SUP], Simone de Nitto[SUP] 1 [/SUP], Brandon M Henry[SUP] 3 [/SUP], Stefano Porru[SUP] 4 [/SUP], Giuseppe Lippi[SUP] 4 [/SUP]
Affiliations
Abstract
in English, Serbian
Background: Since universal vaccinations represents the most effective strategy to mitigate coronavirus disease 2019 (COVID-19), baseline assessment and post-vaccine monitoring of anti-SARS-CoV-2 neutralizing antibodies are essential to vaccination programs. Therefore, this study aimed to compare data of five commercial anti-SARS-CoV2 immunoassays after administration of an mRNA vaccine.
Methods: Venous blood was collected from three healthcare workers, receiving a double (30 g) dose of BNT162b2 mRNA Covid-19 vaccine (Comirnaty, Pfizer), on the day of the first vaccine dose and then at fixed intervals for the following 2 months. Anti-SARS-CoV-2 neutralizing antibody response was assayed with Roche Total Ig anti-RBD (receptor binding domain), DiaSorin TrimericS IgG (spike trimer), Beckman Coulter IgG anti-RBD, SNIBE IgG anti-RBD and Technogenetics IgG anti-N/S1.
Results: A total number of 45 samples were drawn at the end of the 2-month study period. The Spearman's correlations of absolute anti-SARS-CoV-2 antibodies were always excellent (all p<0.001), comprised between 0.967-0.994. Satisfactory results were also observed when absolute antiSARS-CoV-2 antibodies values of the five methods were compared with the mean consensus value, with correlations always higher than 0.979 (all p<0.001). The agreement of anti-SARS-CoV-2 antibodies positivity versus the consensus median positivity ranged between 0.764 and 1.000 (always p<0.001), but become always >0.900 after readjustment of one assay cutoff.
Conclusions: All the immunoassays evaluated in this study appear suitable for monitoring anti-SARS-CoV-2 neutralizing antibodies response in subjects undergoing mRNA COVID-19 vaccination.
Keywords: BNT162b2 mRNA Covid-19 vaccine; antibodies; immune response; immunoassays comparison.
. 2021 Sep 3;40(4):335-340.
doi: 10.5937/jomb0-31475.
Comparison of five commercial anti-SARS-CoV-2 total antibodies and IgG immunoassays after vaccination with BNT162b2 mRNA
Elisa Danese[SUP] 1 [/SUP], Martina Montagnana[SUP] 1 [/SUP], Gian Luca Salvagno[SUP] 1 2 [/SUP], Matteo Gelati[SUP] 1 [/SUP], Denise Peserico[SUP] 1 [/SUP], Laura Pighi[SUP] 1 [/SUP], Simone de Nitto[SUP] 1 [/SUP], Brandon M Henry[SUP] 3 [/SUP], Stefano Porru[SUP] 4 [/SUP], Giuseppe Lippi[SUP] 4 [/SUP]
Affiliations
- PMID: 34616223
- PMCID: PMC8451228
- DOI: 10.5937/jomb0-31475
Abstract
in English, Serbian
Background: Since universal vaccinations represents the most effective strategy to mitigate coronavirus disease 2019 (COVID-19), baseline assessment and post-vaccine monitoring of anti-SARS-CoV-2 neutralizing antibodies are essential to vaccination programs. Therefore, this study aimed to compare data of five commercial anti-SARS-CoV2 immunoassays after administration of an mRNA vaccine.
Methods: Venous blood was collected from three healthcare workers, receiving a double (30 g) dose of BNT162b2 mRNA Covid-19 vaccine (Comirnaty, Pfizer), on the day of the first vaccine dose and then at fixed intervals for the following 2 months. Anti-SARS-CoV-2 neutralizing antibody response was assayed with Roche Total Ig anti-RBD (receptor binding domain), DiaSorin TrimericS IgG (spike trimer), Beckman Coulter IgG anti-RBD, SNIBE IgG anti-RBD and Technogenetics IgG anti-N/S1.
Results: A total number of 45 samples were drawn at the end of the 2-month study period. The Spearman's correlations of absolute anti-SARS-CoV-2 antibodies were always excellent (all p<0.001), comprised between 0.967-0.994. Satisfactory results were also observed when absolute antiSARS-CoV-2 antibodies values of the five methods were compared with the mean consensus value, with correlations always higher than 0.979 (all p<0.001). The agreement of anti-SARS-CoV-2 antibodies positivity versus the consensus median positivity ranged between 0.764 and 1.000 (always p<0.001), but become always >0.900 after readjustment of one assay cutoff.
Conclusions: All the immunoassays evaluated in this study appear suitable for monitoring anti-SARS-CoV-2 neutralizing antibodies response in subjects undergoing mRNA COVID-19 vaccination.
Keywords: BNT162b2 mRNA Covid-19 vaccine; antibodies; immune response; immunoassays comparison.